Arrow and Novartis Agree on RSV
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 62 (Table of Contents)
Published: 5 Aug-2005
DOI: 10.3833/pdr.v2005.i62.642 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Arrow Therapeutics and Novartis entered into licensing agreement for Arrow’s phase 2 small molecule A-60444 for treating respiratory syncytial virus (RSV) infections...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS